1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Giovannucci E and Michaud D: The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132: 2208-2225, 2007.
3. Gunter MJ and Leitzmann MF: Obesity and colorectal cancer: Epidemiology, mechanisms and candidate genes. J Nutr Biochem 17: 145-156, 2006.
4. Cade WT: Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther 88: 1322-1335, 2008.
5. Calle EE, Rodriguez C, Walker Thurmond K and Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348: 1625-1638, 2003.
6. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and Yee D: Diabetes and cancer: A consensus report. Diabetes Care 33: 1674-1685, 2010.
7. Kasuga M, Ueki K, Tajima N, Noda M, Ohashi K, Noto H, Goto A, Ogawa W, Sakai R, Tsugane S, et al: Report of the Japan diabetes Society/Japanese cancer association joint committee on diabetes and cancer. Cancer Sci 104: 965-976, 2013.
8. Ishino K, Mutoh M, Totsuka Y and Nakagama H: Metabolic syndrome: A novel high-risk state for colorectal cancer. Cancer Lett 334: 56-61, 2013.
9. Pais R, Silaghi H, Silaghi AC, Rusu ML and Dumitrascu DL: Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 15: 5141-5148, 2009.
10. Shimizu M, Kubota M, Tanaka T and Moriwaki H: Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int J Mol Sci 13: 579-595, 2012.
11. Wu D, Hu D, Chen H, Shi G, Fetahu IS, Wu F, Rabidou K, Fang R, Tan L, Xu S, et al: Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature 559: 637-641, 2018.
12. Hata K, Kubota M, Shimizu M, Moriwaki H, Kuno T, Tanaka T, Hara A and Hirose Y: Monosodium glutamate-induced diabetic mice are susceptible to azoxymethane induced colon tumorigenesis. Carcinogenesis 33: 702-707, 2012.
13. Tuominen I, Al-Rabadi L, Stavrakis D, Karagiannides I, Pothoulakis C and Bugni JM: Diet-induced obesity promotes colon tumor development in azoxymethane treated mice. PLoS One 8: e60939, 2013.
14. Fukuta K, Shirakami Y, Maruta A, Obara K, Iritani S, Nakamura N, Kochi T, Kubota M, Sakai H, Tanaka T and Shimizu M: Preventive effects of pentoxifylline on the development of colonic premalignant lesions in obese and diabetic mice. Int J Mol Sci 18: pii: E413, 2017.
15. Kubota M, Shimizu M, Sakai H, Yasuda Y, Terakura D, Baba A, Ohno T, Tsurumi H, Tanaka T and Moriwaki H: Preventive effects of curcumin on the development of azoxymethane induced colonic preneoplastic lesions in male C57BL/KsJ-db/db obese mice. Nutr Cancer 64: 72-79, 2012.
16. Shimizu M, Shirakami Y, Sakai H, Adachi S, Hata K, Hirose Y, Tsurumi H, Tanaka T and Moriwaki H: (-)-Epigallocatechin gallate suppresses azoxymethane induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res (Phila) 1: 298-304, 2008.
17. Chang YT, Tsai HL, Kung YT, Yeh YS, Huang CW, Ma CJ, Chiu HC and Wang JY: Dose-dependent relationship between metformin and colorectal cancer occurrence among patients with type 2 Diabetes-A nationwide cohort study. Transl Oncol 11: 535-541, 2018.
18. Horibe Y, Adachi S, Ohno T, Goto N, Okuno M, Iwama M, YamauchiO, KojimaT, SaitoK, IbukaT, etal: Alpha-glucosidase inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: A retrospective study. Oncotarget 8: 97862-97870, 2017.
19. Imamura M, Nakanishi K, Suzuki T, Ikegai K, Shiraki R, Ogiyama T, Murakami T, Kurosaki E, Noda A, Kobayashi Y, et al: Discovery of ipragliflozin (ASP1941): A novel C glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem 20: 3263-3279, 2012.
20. Tahrani AA, Barnett AH and Bailey CJ: SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol 1: 140-151, 2013.
21. Fonseca VA, Ferrannini E, Wilding JP, Wilpshaar W, Dhanjal P, Ball G and Klasen S: Active and placebo controlled dose finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications 27: 268-273, 2013.
22. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Li Q, Tomiyama H, et al: Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin induced type 1 diabetic rats. J Pharm Pharmacol 66: 975-987, 2014.
23. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, et al: Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 385: 423-436, 2012.
24. Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, et al: Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer 142: 1712-1722, 2018.
25. Obara K, Shirakami Y, Maruta A, Ideta T, Miyazaki T, Kochi T, Sakai H, Tanaka T, Seishima M and Shimizu M: Preventive effects of the sodium glucose cotransporter 2 inhibitor tofo- gliflozin on diethylnitrosamine induced liver tumorigenesis in obese and diabetic mice. Oncotarget 8: 58353-58363, 2017.
26. Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, Moatamed NA, Huang J, Koepsell H, Barrio JR and Wright EM: Functional expression of sodium glucose transporters in cancer. Proc Natl Acad Sci USA 112: E4111-E4119, 2015.
27. Utsunomiya K, Shimmoto N, Senda M, Kurihara Y, Gunji R, Kameda H, Tamura M, Mihara H and Kaku K: Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis. J Diabetes Investig 7: 755-763, 2016.
28. Terakura D, Shimizu M, Iwasa J, Baba A, Kochi T, Ohno T, Kubota M, Shirakami Y, Shiraki M, Takai K, et al: Preventive effects of branched-chain amino acid supplementation on the spontaneous development of hepatic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Carcinogenesis 33: 2499-2506, 2012.
29. Hata K, Tanaka T, Kohno H, Suzuki R, Qiang SH, Yamada Y, Oyama T, Kuno T, Hirose Y, Hara A and Mori H: Beta-catenin-accumulated crypts in the colonic mucosa of juvenile ApcMin/+ mice. Cancer Lett 239: 123-128, 2006.
30. Miyazaki T, Shirakami Y, Kubota M, Ideta T, Kochi T, Sakai H, Tanaka T, Moriwaki H and Shimizu M: Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice. Oncotarget 7: 10448-10458, 2016.
31. Shirakami Y, Shimizu M, Kubota M, Ohno T, Kochi T, Nakamura N, Sumi T, Tanaka T, Moriwaki H and Seishima M: Pentoxifylline prevents nonalcoholic steatohepatitis related liver pre neoplasms by inhibiting hepatic inflammation and lipogenesis. Eur J Cancer Prev 25: 206-215, 2016.
32. Shirakami Y, Gottesma n ME and Blaner WS: Diethylnitrosamine-induced hepatocarcinogenesis is suppressed in lecithin:retinol acyltransferase-deficient mice primarily through retinoid actions immediately after carcinogen administration. Carcinogenesis 33: 268-274, 2012.
33. Nagata T, Fukuzawa T, Takeda M, Fukazawa M, Mori T, Nihei T, Honda K, Suzuki Y and Kawabe Y: Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 170: 519-531, 2013.
34. Bird RP and Good CK: The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 112-113: 395-402, 2000.
35. Yamada Y and Mori H: Pre-cancerous lesions for colorectal cancers in rodents: A new concept. Carcinogenesis 24: 1015-1019, 2003.
36. Kubota M, Shimizu M, Sakai H, Yasuda Y, Ohno T, Kochi T, Tsurumi H, Tanaka T and Moriwaki H: Renin-angiotensin system inhibitors suppress azoxymethane induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Biochem Biophys Res Commun 410: 108-113, 2011.
37. Szlosarek P, Charles KA and Balkwill FR: Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 42: 745-750, 2006.
38. Chen J, Wu A, Sun H, Drakas R, Garofalo C, Cascio S, Surmacz E and Baserga R: Functional significance of type 1 insulin-like growth factor-mediated nuclear translocation of the insulin receptor substrate-1 and beta-catenin. J Biol Chem 280: 29912-29920, 2005.
39. Itzkowitz SH and Yio X: Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation. Am J Physiol Gastrointest Liver Physiol 287: G7-G17, 2004.
40. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL and Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
41. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA and Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830, 2003.
42. De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R and van Eijck CH: Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg 100: 1421-1429, 2013.
43. Gonzalez N, Prieto I, Del Puerto Nevado L, Portal Nuñez S, Ardura JA, Corton M, Fernández Fernández B, Aguilera O, Gomez Guerrero C, Mas S, et al: 2017 update on the relationship between diabetes and colorectal cancer: Epidemiology, potential molecular mechanisms and therapeutic implications. Oncotarget 8: 18456-18485, 2017.
44. Xu L, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G, Mayoux E, Kaneko S and Ota T: SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in Diet-induced obese mice. EBioMedicine 20: 137-149, 2017.
45. Ealey KN, Xuan W, Lu S and Archer MC: Colon carcinogenesis in liver specific IGF I deficient (LID) mice. Int J Cancer 122: 472-476, 2008.
46. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE and Hankinson SE: A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9: 345-349, 2000.
47. Olivo-Marston SE, Hursting SD, Lavigne J, Perkins SN, Maarouf RS, Yakar S and Harris CC: Genetic reduction of circulating insulin like growth factor 1 inhibits azoxymethane induced colon tumorigenesis in mice. Mol Carcinog
48: 1071-1076, 2009. 48. Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, et al: Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter 2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: A combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol 13: 65, 2014.
49. Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, Takeda M, Yata T, Kawai M, Fukuzawa T, et al: Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 341: 692 701, 2012.
50. Chao EC and Henry RR: SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov 9: 551-559, 2010.
51. Hanabata Y, Nakajima Y, Morita K, Kayamori K and Omura K: Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma. Odontology 100: 156-163, 2012.
52. Lai B, Xiao Y, Pu H, Cao Q, Jing H and Liu X: Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma. Arch Gynecol Obstet 285: 1455-1461, 2012.
53. Liu H, Ertay A, Peng P, Li J, Liu D, Xiong H, Zou Y, Qiu H, Hancock D, Yuan X, et al: SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity. Mol Oncol 13: 1874-1886, 2019.
54. Madunić IV, Madunić J, Breljak D, Karaica D and Sabolić I: Sodium-glucose cotransporters: New targets of cancer therapy? Arh Hig Rada Toksikol 69: 278-285, 2018.
55. Ren J, Bollu LR, Su F, Gao G, Xu L, Huang WC, Hung MC and Weihua Z: EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors. Prostate 73: 1453-1461, 2013.
56. Rosenwasser RF, Rosenwasser JN, Sutton D, Choksi R and Epstein B: Tofogliflozin: A highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 50: 739-745, 2014.